Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
32.3M
-
Number of holders
-
42
-
Total 13F shares, excl. options
-
2.81M
-
Shares change
-
-895K
-
Total reported value, excl. options
-
$3.51M
-
Value change
-
-$1.51M
-
Number of buys
-
25
-
Number of sells
-
-30
-
Price
-
$1.25
Significant Holders of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) as of Q2 2025
58 filings reported holding TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value as of Q2 2025.
Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) has 42 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.81M shares
of 32.3M outstanding shares and own 8.7% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.12M shares), BlackRock, Inc. (370K shares), MILLENNIUM MANAGEMENT LLC (248K shares), GEODE CAPITAL MANAGEMENT, LLC (197K shares), GOLDMAN SACHS GROUP INC (161K shares), MARSHALL WACE, LLP (75.8K shares), Y-Intercept (Hong Kong) Ltd (64.4K shares), STATE STREET CORP (61.6K shares), Bank of New York Mellon Corp (51.5K shares), and Suncoast Equity Management (51.2K shares).
This table shows the top 42 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.